Paper41007643
Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier.
Tiwari A and 9 others. Biomedicines, 2025. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier. Papers, record 41007643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39558940 | Resmetirom. | Hosp Pharm | 2025 | https://conductscience.org/library/papers/39558940 | PubMed |
| 2 | 39621874 | Safety and efficacy of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a systematic review and meta-analysis. | Eur J Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/39621874 | PubMed |
| 3 | 37845512 | Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. | Nat Med | 2023 | https://conductscience.org/library/papers/37845512 | PubMed |
| 4 | 39420154 | Actions of thyroid hormones and thyromimetics on the liver. | Nat Rev Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/39420154 | PubMed |
| 5 | 33185364 | A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33185364 | PubMed |
| 6 | 21990298 | Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). | JAMA | 2011 | https://conductscience.org/library/papers/21990298 | PubMed |
| 7 | 39150005 | Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis. | J Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/39150005 | PubMed |
| 8 | 28670712 | Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. | J Gastroenterol Hepatol | 2018 | https://conductscience.org/library/papers/28670712 | PubMed |
| 9 | 22297845 | Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. | Nature | 2012 | https://conductscience.org/library/papers/22297845 | PubMed |
| 10 | 39126031 | NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39126031 | PubMed |
| 11 | 36910628 | Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis. | Front Oncol | 2023 | https://conductscience.org/library/papers/36910628 | PubMed |
| 12 | 38851997 | EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). | J Hepatol | 2024 | https://conductscience.org/library/papers/38851997 | PubMed |
| 13 | 24075770 | Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist. | Atherosclerosis | 2013 | https://conductscience.org/library/papers/24075770 | PubMed |
| 14 | 39187533 | Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. | Sci Rep | 2024 | https://conductscience.org/library/papers/39187533 | PubMed |
| 15 | 24712661 | Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia. | J Med Chem | 2014 | https://conductscience.org/library/papers/24712661 | PubMed |
| 16 | 26549695 | Obeticholic acid for the treatment of primary biliary cirrhosis. | Expert Rev Clin Pharmacol | 2016 | https://conductscience.org/library/papers/26549695 | PubMed |
| 17 | 36626630 | The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. | Hepatology | 2023 | https://conductscience.org/library/papers/36626630 | PubMed |
| 18 | 30300287 | Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. | Transplantation | 2019 | https://conductscience.org/library/papers/30300287 | PubMed |
| 19 | 12888625 | Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. | Proc Natl Acad Sci U S A | 2003 | https://conductscience.org/library/papers/12888625 | PubMed |
| 20 | 37786277 | Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. | Aliment Pharmacol Ther | 2024 | https://conductscience.org/library/papers/37786277 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42883860 | Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the "Liver-Other Organs" Axes. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42883860 | PubMed |
| 42864313 | Hydrogen peroxide sensing and signaling in physiology and disease: implications for therapy. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42864313 | PubMed |
| 42796348 | Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42796348 | PubMed |
| 42706950 | From targeted drug delivery to tissue regeneration: the evolving role of nanoparticle therapies in liver disease. | Regen Med | 2026 | https://conductscience.org/library/papers/42706950 | PubMed |
| 42666480 | Metabolic dysfunction-associated steatotic liver disease as a systemic disorder: extrahepatic manifestations and the need for data-driven phenotyping. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42666480 | PubMed |
| 42612975 | Targeting microbial bile salt hydrolase reprograms bile acid metabolism and ameliorates metabolic dysfunction-associated steatohepatitis in mice. | Mol Metab | 2026 | https://conductscience.org/library/papers/42612975 | PubMed |
| 42496289 | FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches. | Medicines (Basel) | 2026 | https://conductscience.org/library/papers/42496289 | PubMed |
| 42182451 | Targeting Microbial Bile Salt Hydrolase Reprograms Bile Acid Metabolism and Ameliorates Metabolic Dysfunction-Associated Steatohepatitis in Mice. | bioRxiv | 2026 | https://conductscience.org/library/papers/42182451 | PubMed |
| 41983208 | Dapagliflozin for metabolic dysfunction-associated steatohepatitis with fibrosis: a promising therapeutic agent in biopsy-diagnosed patients. | Hepatobiliary Surg Nutr | 2026 | https://conductscience.org/library/papers/41983208 | PubMed |
| 41617025 | HIF-2α induction in de novo lipogenesis in metabolic dysfunction-associated steatohepatitis is dependent on IL-21 signaling. | J Biol Chem | 2026 | https://conductscience.org/library/papers/41617025 | PubMed |
| 41595685 | The Role of Kupffer Cells and Liver Macrophages in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease. | Biomedicines | 2026 | https://conductscience.org/library/papers/41595685 | PubMed |
| 41463398 | Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure and Cancer. | Biomolecules | 2025 | https://conductscience.org/library/papers/41463398 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41007643
GET https://conductscience.org/api/papers/v1/41007643/references?page=2